➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Harvard Business School
Dow
Merck
McKesson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,144,944

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,144,944
Title:Methods of cell culture
Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
Inventor(s): Prentice; Holly (Carlisle, MA)
Assignee: Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/496,368
Patent Claims:1. A method of producing an adalimumab preparation having a target value of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans, the method comprising: (a) providing a cell genetically engineered to express adalimumab; (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab; and (c) harvesting a preparation of the adalimumab produced by the cell that meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans, wherein the target value of fucosylated glycans, galactosylated glycans, or sialylated glycans is a level at least 10% higher than a level of fucosylated glycans, galactosylated glycans, or sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine; or wherein the target value of high mannose glycans is a level at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.

2. The method of claim 1, wherein the target value is a level of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans in a reference preparation of adalimumab.

3. The method of claim 1, further comprising evaluating a level of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans in the adalimumab preparation.

4. The method of claim 1, wherein the target value is one or more of: (a) 70% to 100% fucosylated glycans; (b) 1% to 95% galactosylated glycans; (c) 0.1% to 20% high mannose glycans; and (d) 0.1% to 90% sialylated glycans.

5. The method of claim 1, wherein the culture medium further comprises one or more of lysine, ammonium, DMSO, copper, glucose, a growth factor, a vitamin, a lipid, and a peptone.

6. A method of producing an adalimumab preparation, the method comprising: (a) providing a target value of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans; (b) providing a cell genetically engineered to express adalimumab; (c) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab; (d) harvesting a preparation of the adalimumab produced by the cell; and (e) formulating the adalimumab preparation into a drug product if the adalimumab preparation meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans; wherein the target value of fucosylated glycans, galactosylated glycans, or sialylated glycans is a level at least 10% higher than a level of fucosylated glycans, galactosylated glycans, or sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine; or wherein the target value of high mannose glycans is a level at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.

7. The method of claim 6, further comprising evaluating a level of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans in the adalimumab preparation.

8. The method of claim 6, wherein the culture medium further comprises one or more of lysine, ammonium, DMSO, copper, glucose, a growth factor, a vitamin, a lipid, and a peptone.

9. A method of increasing a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans in an adalimumab preparation, the method comprising: (a) providing a cell genetically engineered to express adalimumab; (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab; and (c) harvesting a preparation of adalimumab produced by the cell, wherein the adalimumab preparation has a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans that is at least 10% higher than a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.

10. The method of claim 9, further comprising evaluating a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans.

11. The method of claim 9, wherein the culture medium further comprises one or more of lysine, ammonium, DMSO, copper, glucose, a growth factor, a vitamin, a lipid, and a peptone.

12. A method of decreasing a level of one or more high mannose glycans in an adalimumab preparation, the method comprising: (a) providing a cell genetically engineered to express adalimumab; (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab; and (c) harvesting a preparation of the adalimumab produced by the cell, wherein the adalimumab preparation has a level of high mannose glycans that is at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.

13. The method of claim 12, further comprising evaluating a level of the one or more high mannose glycans.

14. The method of claim 12, wherein the culture medium further comprises one or more of lysine, ammonium, DMSO, copper, glucose, a growth factor, a vitamin, a lipid, and a peptone.

15. The method of any one of claim 1, 6, 9, or 12, wherein the culturing step comprises a first stage and a second stage, wherein the first stage comprises culturing the cell in the culture medium comprising a first level of putrescine, and the second stage comprises culturing the cell in the culture medium comprising a second level of putrescine which is increased relative to the first level.

16. The method of claim 15, wherein the second level is 0.1 mg/L to 10 mg/L putrescine.

17. The method of claim 15, wherein the first stage comprises culturing the cell in the first level of putrescine for 1 to 8 days.

18. The method of claim 17, wherein the second stage comprises culturing the cell in the second level of putrescine for 1 to 12 days.

19. The method of any one of claim 1, 6, 9, or 12, wherein the cell is a Chinese Hamster Ovary (CHO) cell.

20. The method of claim 3 or 7, further comprising recording the evaluated level of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans in a batch record for the preparation.

21. The method of claim 10, further comprising recording the evaluated level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans in a batch record for the preparation.

22. The method of claim 13, further comprising recording the evaluated level of one or more high mannose glycans in a batch record for the preparation.

23. The method of any one of claim 1, 6, 9, or 12, wherein the culturing step comprises adding putrescine to the culture medium.

Details for Patent 10,144,944

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2033-03-14 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Momenta Pharmaceuticals, Inc. (Cambridge, MA) 2033-03-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
McKinsey
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.